Rowland Charles A Jr
Director at VKTX; Director at Nabriva Therapeutics AG; Director at BPMC, and 1 more
- Sold, on record
- $9.8M
- Dollars the filings state
- Form 4 sales
- 9
- Latest Oct 27, 2025
- Form 144 notices
- 2
- Proposed sales
- Companies
- 4
- Filed as an executive or holder
Companies
- VKTXViking Therapeutics, Inc.Director
- Nabriva Therapeutics AGDirector
- BPMCBlueprint Medicines CorpDirector
- VIROPHARMA INCVP, Chief Financial Officer
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
- VIROPHARMA INC117,750 shares
- VKTX100,000 shares
- BPMC32,727 shares
- Nabriva Therapeutics AG9,273 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale BPMCUnusualNov 3, 2020 2020
Sold 10,000 shares at $98.90 ($989k)
Rowland Charles A Jr, Director
Sold 73.7% of holdings ($1.3M position)3,562 shares leftFiling
- 2 Form 4 sale BPMCUnusualDec 17, 2020 +44 days
Sold 10,909 shares at $117.82 ($1.3M)
Rowland Charles A Jr, Director
Sold 75.4% of holdings ($1.7M position)3,562 shares leftFiling
- 3 Form 4 sale Nabriva Therapeutics AGPlan not statedAug 2, 2021 +228 days
Sold 777 shares at $1.20 ($932)
Rowland Charles A Jr, Director
Sold 3.2% of holdings ($29k position)23,773 shares leftFirst sale on recordFiling
- 4 Form 4 sale Nabriva Therapeutics AGUnusualAug 1, 2022 +364 days
Sold 8,496 shares at $0.18 ($2k)
Rowland Charles A Jr, Director
Sold 35.7% of holdings ($4k position)15,277 shares leftFiling
- 5 Form 144 notice VKTXNoticeMay 16, 2023 +288 days
Filed to sell 40,000 shares ($1M)
Rowland Charles A Jr, Director
No 10b5-1 planFirst sale on recordFiling
- 6 Form 4 sale VKTXUnusualMay 16, 2023 same day
Sold 40,000 shares at $25.00 ($1M)
Rowland Charles A Jr, Director
No 10b5-1 planSold 57.1% of holdings ($1.8M position)30,000 shares leftFirst sale on recordFiling
- 7 Form 144 notice VKTXNoticeOct 27, 2025 +895 days
Filed to sell 60,000 shares ($2.1M)
Rowland Charles A Jr, Director
No 10b5-1 planFirst sale on recordFiling
- 8 Form 4 sale VKTXUnusualOct 27, 2025 same day
Sold 60,000 shares at $35.57 ($2.1M)
Rowland Charles A Jr, Director
No 10b5-1 planSold 66.7% of holdings ($3.2M position)30,000 shares leftFirst sale on recordFiling
Every transaction
Loading transactions…
Sales and notices (11)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Oct 27, 2025 | Oct 28, 2025 | VKTX | Director | Form 4 sale | 60,000 | $2.1M | 66.7% | Unusual | SEC |
| Oct 27, 2025 | Oct 27, 2025 | VKTX | Director | Form 144 notice | 60,000 | $2.1M | Notice | SEC | |
| May 16, 2023 | May 18, 2023 | VKTX | Director | Form 4 sale | 40,000 | $1M | 57.1% | Unusual | SEC |
| May 16, 2023 | May 16, 2023 | VKTX | Director | Form 144 notice | 40,000 | $1M | Notice | SEC | |
| Aug 1, 2022 | Aug 3, 2022 | Nabriva Therapeutics AG | Director | Form 4 sale | 8,496 | $2k | 35.7% | Unusual | SEC |
| Aug 2, 2021 | Aug 4, 2021 | Nabriva Therapeutics AG | Director | Form 4 sale | 777 | $932 | 3.2% | Plan not stated | SEC |
| Dec 17, 2020 | Dec 18, 2020 | BPMC | Director | Form 4 sale | 10,909 | $1.3M | 75.4% | Unusual | SEC |
| Nov 3, 2020 | Nov 4, 2020 | BPMC | Director | Form 4 sale | 10,000 | $989k | 73.7% | Unusual | SEC |
| Jun 20, 2019 | Jun 24, 2019 | BPMC | Director | Form 4 sale | 11,818 | $1.1M | 100.0% | Unusual | SEC |
| Mar 1, 2012 | Mar 5, 2012 | VIROPHARMA INC | VP, Chief Financial Officer | Form 4 sale | 82,750 | $2.7M | 82.9% | Unusual | SEC |
| Mar 14, 2011 | Mar 15, 2011 | VIROPHARMA INC | VP, Chief Financial Officer | Form 4 sale | 35,000 | $650k | 55.1% | Unusual | SEC |